Semprus BioSciences Inc. tapped a veteran of the pharmaceutical world and a prominent MIT professor for its scientific advisory board.
Colin Gardner and Michael Cima will join the Cambridge, Mass.-based medical device coatings developer’s science panel effective immediately.
Gardner, a private industry consultant, put in time as chief scientific officer at TransForm Pharmaceuticals, which was acquired in 2005 by Johnson & Johnson (NYSE:JNJ). After the buyout he stayed on as senior vice president of research and site leader for TransForm. His resumé also includes a stint at Merck & Co. (NYSE:MRK).
It’s just the latest appointment for Cima, the Sumitomo Electric Industries Professor in the Materials Science and Engineering Dept. at MIT, who’s already on the board of a number of medical device and biotech firms. Cima is co-founder and director of MicroChips Inc., Taris Biomedical Inc., Entra Pharmaceuticals Inc., T2 Biosystems Inc. and was a senior consultant and a member of the management team at TransForm.
Semprus is developing what it calls “the first complication-free, anti-biofilm, anti-thrombogenic” coating for medical devices, according to a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.